The Global Unite reverse fracture shoulder implant was released by Johnson & Johnson subsidiary DePuy Synthes for use in post-complex fracture shoulder reconstruction procedures in patients with grossly deficient rotator cuffs. The system, which comes with a Porocoat porous coating and numerous suture holes and pockets for better bone fixation around the implant, is designed to improve flexibility for secure reattachment of the bone to the implant.
Several protocol changes were made by Cellectis in an effort to advance its Phase I study for its chimeric antigen receptor T-cell candidate UCART123 to treat patients with acute myeloid leukemia. The changes include the addition of MD Anderson Cancer Center to boost enrollment and a 400% increase in dose levels to be administered, and a shorter observation period for dose-limiting toxicities.
A long-term strategic drug discovery and development collaboration was signed by Celgene and Evotec to identify oncology therapies. Under the terms of the deal, Celgene gets exclusive opt-in rights to license worldwide rights to all programs developed within the collaboration, while Evotec will receive an upfront payment of $65 million and is eligible for milestone and royalty payments.
The proposed $66 billion acquisition of biotechnology firm Monsanto by Germany-based Bayer was approved by the Competition Commission of India. Under the deal, Bayer's significant crop science and pharmaceutical business will be combined with Monsanto's seed business in India.
The Pennsylvania Department of Environmental Protection's Alternative Fuels Incentive Grant Program grants funding for the purchase and use of alternative fuels and alternative fuel vehicles. This year's program will prioritize projects that include vehicles used by emergency personnel in evacuations, emergency responses and rescues.
Varian Medical, which initially offered to buy Sirtex Medical for $1.28 billion, said it won't submit a counterproposal to Chinese alternative asset manager CDH Investments' $1.41 billion counteroffer for Sirtex. "The board of directors of Sirtex has not yet formed a view on these matters and continues to unanimously support and recommend the Varian Scheme," a statement from Varian said.
A round of Series B financing brought in $8.5 million for Carlsbad, Calif.-based eye-care focused device company Tear Film Innovations, which makes the iLux system for the treatment of blocked meibomian glands in the eyelids. The proceeds will support Tear's growth strategy as the company expands its team to meet the demand for its product.
Olympus agreed to exclusively distribute M.I. Tech's Hanarostent self-expanding metal biliary and esophageal stents through its US distribution networks in the gastrointestinal market. The companies will also collaborate on how other products from M.I. Tech can obtain regulatory approval and be commercialized.